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Oral ingestion has been the most convenient and commonly used route of drug ad-
ministration because of its flexibility and dosage form design (1). In the immediate re-
lease (IR) dosage form, there is little or no control of drug release from the dosage form,
which often results in constantly changing, unpredictable, and often sub- and supra-the-
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Extended release formulation of tramadol hydrochloride
(TRH) based on osmotic technology was developed and
evaluated. Target release profile was selected and differ-
ent variables were optimized to achieve it. Formulation
variables such as the level of swellable polymer, plasti-
cizer and the coat thickness of semipermeable membrane
(SPM) were found to markedly affect drug release. TRH
release was directly proportional to the levels of plasti-
cizer but inversely proportional to the levels of swellable
polymer and coat thickness of SPM. Drug release from
developed formulations was independent of pH and agi-
tation intensity but dependent on osmotic pressure of the
release media. In vivo study was also performed on six
healthy human volunteers and various pharmacokinetic
parameters (cmax, tmax, AUC0–24, MRT) and relative bio-
availability were calculated. The in vitro and in vivo re-
sults were compared with the performance of two com-
mercial TRH tablets. The developed formulation provided
more prolonged and controlled TRH release compared to
the marketed formulation. In vitro-in vivo correlation
(IVIVC) was analyzed according to the Wagner-Nelson
method. The optimized formulation (batch IVB) exhibited
good IVIV correlation (R = 0.9750). The manufacturing
procedure was found to be reproducible and formulations
were stable over 6 months of accelerated stability testing.
Keywords: tramadol, extended release, osmotic pressure,
swellable polymer, in vitro-in vivo correlation
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rapeutic plasma concentrations (2). Controlled release (CR) systems have been introdu-
ced to overcome the drawback associated with IR dosage forms. Among the various CR
formulations available, per-oral controlled release (CR) holds the major market share be-
cause of its advantages such as ease of administration and better patient compliance (3).
The majority of per-oral CR dosage forms fall in the category of matrix, reservoir or
osmotic systems. Drug release from matrix and reservoir systems is affected by pH, hy-
drodynamic conditions and the presence of food in the gastro-intestinal tract (2). Osmo-
tic systems utilize the principles of osmotic pressure for controlled delivery of drugs (4).
Drug release from these systems is to a large extent independent of pH and other physi-
ological parameters (5). The development of oral osmotic systems has a large market po-
tential, as evident from the marketed products and number of patents granted in the last
few years (6, 7).
Tramadol hydrochloride (TRH), a centrally acting opioid analgesic, is used in severe
acute or chronic pains (8). It offers several therapeutic advantages over other analgesics,
such as good oral bioavailability and long elimination half-life (5–7 h). Despite the long
elimination half-life, TRH is prescribed 3–4 times a day (9). Frequent dosing schedule of-
ten leads to decreased patient compliance, increased incidence of side effects and toler-
ance development, especially, in long-term use (10) in conditions like arthritis, osteoar-
thritis, arthralgia, postoperative surgical pains, etc. It seems that there is a strong clinical
need and market potential for a delivery system that can deliver TRH in a controlled
manner.
The present study was thus aimed at the development of extended release formula-
tion of TRH based on osmotic technology.
EXPERIMENTAL
Materials
Tramadol hydrochloride (98.7 % purity) was obtained from Win Medicare Ltd, In-
dia. Polyethylene oxide (Mr 300000) was a received from Torrent Research Centre, India.
The following chemicals and excipients were purchased from commercial sources and
were used as such: cellulose acetate (39.8 % acetylation), polyvinyl pyrrolidone (PVP K-30),
microcrystalline cellulose (MCC pH 102), magnesium stearate, talc, sodium chloride (all
from CDH, India), acetone, methanol (HPLC grade), acetonitrile (HPLC grade), trietha-
nolamine, fructose, mannitol (all from Qualigens Fine Chemicals, India), disodium hy-
drogen orthophosphate, orthophosphoric acid (all from S.D. Fine Chemicals, India). TRD
CONTIN® (Modi-Mundi Pharmaceuticals, India, 100 mg sustained release tablet) and
Tramazac® (Zydus Cadila Pharmaceuticals, India, 50 mg conventional tablet) were pur-
chased from a retail pharmacy.
Formulation development
Before initiating formulation development, compatibility of TRH with different ex-
cipients was tested using the techniques of DSC (Du-Pont, Model 9900, USA) and FT-IR
(Shimadzu, Model 8400S, Japan). Excipients used in the final formulation were found to
be compatible with TRH.
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Core tablets of TRH were prepared by direct compression and batch size was 100 tab-
lets. Formulas of different core formulations of TRH are listed in Table I. TRH was mixed
with polyethylene oxide (PEO) for 10 min. After passing this mixture through a sieve
600 mm, osmotic agents (fructose or mannitol), MCC and PVP were added in geometric
dilution and mixing continued for an additional 10 min. To this mix, talc and magnesium
stearate passed through 250 mm sieve, were added and mixing continued for an additional
10 min. The blend was then compressed into tablets of average mass of 300–320 mg using
a single station tablet punching machine (Manesty E-2, UK) fitted with 8 mm round
standard concave punches. The punched tablets were of 6.0 ± 0.38 kg cm–2 hardness on
the Monsanto hardness tester (Campbell Electronics, India).
TRH core tablets were coated in a conventional laboratory coating pan (Scientific In-
strument, India) fitted with three baffles placed at an angle of 120° having the outer di-
ameter of 10 cm (11). The composition of solutions used for coating TRH tablets is given
in Table II. The coating process was done on a batch of 100 tablets; pan speed was main-
tained at 20 rpm and hot air inlet temperature was kept at 38–42 °C (11). The manual
coating procedure based on intermittent spraying and coating was used at a spray rate
of 4–5 mL min–1. Coat mass and thickness were controlled by the volume of coating so-
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I II III IV Va
Tramadol hydrochloride 100 100 100 100 100
Mannitol – 136 136 136 136
Fructose 136 – – – –
PEO – – 30 50 70
MCC 50 50 20 – –
PVP 10 10 10 10 10
Talc 2 2 2 2 2
Magnesium stearate 2 2 2 2 2
PEO – polyethylene oxide, MCC (pH 102) – microcrystalline cellulose, PVP K-30 – polyvinylpyrrolidone
a Batch with average mass of 320 mg. Other batches are of average mass 300 mg.




Cellulose acetate(mg) 4000 4000 4000
PEG-400 (mg) – 400 800
Methanol (mL) 10 10 10
Acetone (mL) 90 90 90
lution consumed in the coating process (11). Coating was continued until the desired coat
thickness (150 mm) was obtained on the core tablets. An appropriate size orifice (0.5 mm)
was made on one face of all the coated tablets using a microdrill (Kamlesh Engineers,
India) (12). In all the cases, coated tablets were dried at 50 °C for 10 h before further
evaluation.
Surface morphology study
To investigate the changes in the membrane structure due to the presence of pla-
sticizer (PEG-400), the surface of coated tablets (both before and after dissolution studies)
was studied using SEM (JEOL, JSM-6100, Japan). The samples were placed on a spherical
brass stub (12 mm diameter) with a double backed adhesive tape. The mounted samples
were sputter coated for 5 to 10 min with gold using a fine coat ion sputter (Jeol, JFC-1100,
Japan) and examined under SEM (Jeol, JSM-6100, Japan).
Evaluation of developed formulation
Bulk and tap density of the powdered blend was determined using the USP method
II (13) and the compressibility index and Hausner ratio were calculated.
The core and coated tablets were evaluated for mass variation. Thickness and diam-
eter of the core and coated tablets were measured using screw gauze (Ultra Science Aid,
India). Hardness of randomly selected tablets was tested using a hardness tester (Mon-
santo hardness tester). Friability of 20 core tablets was carried out on a Cintex friability
test apparatus (Cintex, India).
The developed formulation (n = 3) of TRH was subjected to release studies using a
USP dissolution apparatus type II (Campbell Electronics, India) at 50 rpm (13). Disso-
lution medium used was simulated intestinal fluid (SIF) (pH 6.8, 900 mL) maintained at
37 ± 0.5 °C, which was found to provide sink conditions (solubility of TRH was deter-
mined to be > 0.5 g mL–1) (14). The samples were withdrawn (5 mL) at different time in-
tervals and replaced with equivalent amounts of fresh medium. Dissolution samples, af-
ter filtration through a 0.45-mm nylon membrane filter, were analyzed using an already
reported validated HPLC method at 271 nm (15, 16). After analyzing the drug content in
the dissolution samples, corrections were made for volume replacement and the graph
of cumulative percent of drug release vs. time was plotted.
Release profiles of various batches were compared using a model independent
pairwise approach, which includes calculation of the 'difference factor' f1 and 'similarity
factor' f2. The two release profiles were considered to be similar if f1 value was lower
than 15 (between 0 and 15) and f2 value was more than 50 (between 50 and 100). Release
profiles were also compared using the mean dissolution time (MDT), which was calcu-
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where j is the sample number, n is the number of dissolution sample times, tj
∧
is the time
at mid-point between tj and t(j-1), and DMj is the additional amount of drug dissolved
between tj and t(j-1). One-way analysis of variance test (ANOVA) was performed to check
whether there was a significant difference between different formulations.
In this study, the mean dissolution time for 50 % drug release (MDT50) was used for
comparison of release profiles from different batches.
For content uniformity testing, accurately weighed tablets (n = 20) were dissolved
in 500 mL of distilled water (18). The samples were sonicated for 30 min and filtered
through a 0.45-mm nylon membrane filter. The filtered samples, after appropriate dilution
with the mobile phase, were analyzed at 271 nm using HPLC (Cecil HPLC system, UK).
HPLC analysis
For in vitro and in vivo analysis of drug samples, the Cecil HPLC system equipped
with an adept series dual piston pump CE-4100, manual injector Caplugs RC-11 and
adept series variable wavelength UV/Vis detector CE-4201 was used. Reverse phase
HPLC method was carried out using a phenomenex C-18 column (4.6 ´ 250 mm, 5 mm
particle size) at 25 °C. The optimized mobile phase composition was phosphate buffer
(0.01 mol L–1)/acetonitrile/triethanolamine (75:25:0.1) at a flow rate of 1 mL min–1. In-
jected volume was 20 mL and detection was performed at 271 nm (15, 16).
In vivo studies
In vivo studies were performed following the standard protocols on six healthy hu-
man volunteers of either sex weighing 55–75 kg and 24–29 years old in a crossover de-
sign with a wash-out period of one week. Volunteers agreed in writing to participate in
the study after being informed about the experimental protocol. All the subjects were in
good health according to their medical history and complete medical examination. Hepa-
rinized blood samples were taken at the following times: 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h
post administration and stored at –4 °C till further used.
The experimental protocol was approved by the human ethical committee, Banaras
Hindu University, India.
Plasma samples were prepared by liquid-liquid extraction. Plasma (250 mL) was mixed
with 100 mL NaOH (1 mol L–1) in a 4-mL test tube and then extracted with 1.25 mL of
ethyl acetate. After vertical agitation (10 min) and centrifugation (10,000 rpm, 10 min),
the upper organic layer was transferred into a conical glass tube. Extraction was repeated
using another 1.25 mL of ethyl acetate. The organic phase was then evaporated under a
gentle stream of air and reconstituted in 250 mL of a mobile phase (15, 16).
In vitro-in vivo correlation
In vitro-in vivo correlation of the optimized batch was investigated by plotting the
percent dissolved (Fr) vs. percent absorbed (Fa) drug. Percent dissolved values were taken
from in vitro release data and percent absorbed was determined by the Wagner-Nelson
method using the following equation (19):
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F C k AUC k AUCa t e t e= + ×[( ]0 0 100– –)/  (2)
where Fa is the fraction of drug absorbed, Ct is the drug plasma concentration at time t,
ke is the overall elimination rate constant, AUC0–t, and AUC0– are areas under the curve
between time zero and time t and between time zero and infinity, respectively.
RESULTS AND DISCUSSION
Desired drug release profile
Using the different pharmacokinetic parameters of TRH (Table III), the dose needed
to provide controlled delivery of TRH can be calculated by the following equation (20):
D0 = CpTClT (3)
where D0 is the dose, Cp is the therapeutic drug plasma level, ClT is total clearance and T
is the dosing interval. Therapeutic range for TRH is reported to be between 0.1–0.3 mg
mL–1 (21) and the desired steady state concentration of TRH for a 100 mg (four times a
day) dose is 0. 225 mg mL–1. Taking the steady state concentration as the desired thera-
peutic plasma level and the dosing interval of 12 h, the following values were proposed:
(i) sustaining dose 100 mg, (ii) zero-order release rate 8.1 mg h–1, (iii) dosing interval 12 h.
By plotting the cumulative zero-order release (%) (y) vs. time (x), the desired release pro-
file was generated and used as the target release profile for developed formulations
(y = 8.1x).
Effect of formulation variables
In the initial trial, TRH core tablets (batch I) were coated with the coating composi-
tion code B (formulation code batch IB). Release studies showed that more than 85 % of
the drug was delivered within 5 h (Fig. 1). This may be due to the high solubility of TRH
or high osmotic pressure generation within the core compartment. To reduce the osmotic
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Table III. Various pharmacokinetic parameters of tramadol hydrochloride
Pharmacokinetic parameter Value References
Bioavailability (f) 74 % 8, 9
Elimination half-life (t1/2) 6.3 h 9, 10
Terminal disposition rate constant (Kel) 0.11 h–1 8–10
Apparent volume of distribution (Vd) 2.7 l kg–1 8, 9
Maximum effective conc. (cmax) 0.3 mg mL–1 22
Minimum effective conc. (cmin) 0.1 mg mL–1 22
Total clearance (ClT) 8.5 mL min–1 kg–1 8–10
pressure in the core compartment, mannitol (38 atm, saturated solution) (7) was used in
place of fructose (335 atm, saturated solution) (7) within the core (batch IIB). This ap-
proach was unsuccessful as more than 75 % drug was released within 5 h (Fig. 1).
Osmotic pumps per se are suitable for the delivery of drugs having intermediate wa-
ter solubility (2). It has been reported that in case of water-insoluble drugs, reasonable
release rates may not be obtained using an elementary osmotic pump or controlled-po-
rosity osmotic pump (5). This is because the kinetics of osmotic drug release is directly
related to drug solubility within the core. Assuming a tablet core of pure drug, the frac-
tion of drug released with zero-order kinetics is given by:
F z( ) –= 1 S
r
(4)
where F(z) is the fraction released by zero-order kinetics, S is the drug solubility (g mL–1),
and r is the density (g mL–1) of the core tablet. Drugs with a solubility of  0.05 g mL–1
would be released with  95 % zero-order kinetics according to Eq. (4). However, the






L p Cp= s Dp( – ) (5)
Eq. (5) describes drug release from osmotic pumps, where dm/dt is the drug delivery
rate, A and h are the membrane area and thickness, respectively, c is the concentration
(or the solubility, when excess of drug is present in the core) of the drug in the dispensed
fluid, Dp is the osmotic pressure difference across the film, sLp is the hydraulic perme-
ability of the membrane and p is the hydrostatic pressure within the core compartment.
According to Eq. (4), highly water-soluble drugs would demonstrate a high release
rate, which would be zero-order for a small percentage of the initial drug load. Thus, the
21
P. Kumar et al.: Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on
osmotic technology, Acta Pharm. 59 (2009) 15–30.
Time (h)










Batch IVB (150 m)m
Batch VB
Batch IVB (200 m)m




















Fig. 1. Effect of PEO, plasticizer
level and semipermeable mem-
brane coat thickness on TRH re-
lease release from the developed
formulations. Points represents
mean ± SD (n = 3).
intrinsic water solubility of many drugs might preclude them from incorporation into an
osmotic pump. However, it is possible to modulate the solubility of drugs within the
core, and thus extend this technology for delivery of drugs that may otherwise be poor
candidates for osmotic delivery.
TRH is a basic drug with very high water solubility; pKa value of TRH is 9.41, hence
solubility is also pH independent at physiological pH (11). In order to get the desired re-
lease from the developed systems, PEO was added to the core formulation. After coming
in contact with the surrounding fluid, swellable polymer (PEO) causes significant swell-
ing, which creates significant internal pressure within the osmotic system leading to re-
duced imbibition. Also, the PEO within the core may restrict or delay the contact of sol-
vent molecules with the drug and osmotic agent molecules, which may result in decreased
osmotic pressure generation within the device and thus control the release of the drug
from EOP (22, 23). Three batches were prepared, in which the PEO concentration was
varied. Batches III, IV and V were coated with the coating composition code B and for-
mulations coded as batch IIIB, IVB, VB containing 10 %, 16.6 %, and 23.3 % (m/m) of PEO
respectively. In vitro release profiles of three batches (IIIB, IVB, VB) compared to batch
IIB (without PEO) are compared in Fig. 1. It is clearly evident that the concentration of
PEO has an inverse effect on drug release. With an increase in the PEO concentration
within the core there was a decrease in drug release and an increase in swelling of the
formulations due to higher internal pressure generated by PEO. The differences in MDT50
between the above formulations (1.44, 2.56, 3.01, 3.57 h for batch IIB, IIIB, IVB and VB,
resp.) were found to be statistically significant (p < 0.05).
To study the effect of coat thickness of the semipermeable membrane (SPM) on drug
release, core tablets of TRH (batch IV) were coated with the coating composition code B
so as to give coat thickness of 100, 150 and 200 mm. Release profiles of TRH from these
formulations are shown in Fig. 1. It is clearly evident that drug release decreases with
the increase in coat thickness of SPM. The differences in MDT50 between the above for-
mulations (2.56, 3.19, 4.12 h for 100–150- and 200-mm coat thrickeness) were found to be
statistically significant (p < 0.05).
To study the effect of the level of plasticizer (PEG-400), core formulation (batch IV)
of TRH was coated with coating composition code A and C with no PEG-400 and con-
taining 20 % (m/m) PEG-400 (of cellulose acetate mass), respectively (batches IVA and
IVC). Release profiles of these formulations in comparison with batch IVB [containing 10 %
(m/m) PEG-400 of cellulose acetate mass] are shown in Fig. 1. It is clearly evident that
the level of plasticizer, PEG-400, has a direct effect on drug release. As the level of PEG-400
increases, the membrane becomes more porous due to rapid dissolution of water soluble
PEG-400 in dissolution medium, resulting in higher drug release (11).
In vitro drug release profiles of the promising batches IIIB, IVB and VB were com-
pared with commercial immediate release Tramazac®-50 mg (M1) and sustained release
TRD-CONTIN®-100 mg (M2) formulations of TRH and also with the theoretically de-
sired release profile (Fig. 2). It is clearly evident that the developed formulations pro-
vided more controlled and prolonged drug release compared to commercial formulations
of TRH. Drug release from batch IVB was found to be closest to the desired release pro-
file. The f1 and f2 values for batch IVB were 5.71 and 82.31, respectively, taking the de-
sired release profile as reference, indicating no significant difference between batch IVB
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and the theoretically desired release profile. Formulation IVB was therefore selected as
the optimized formulation and was further evaluated.
Evaluation of the optimized formulation
The optimized batch IVB was evaluated for various pharmacopoeial and non-phar-
macopoeial tests, results of which are listed in Table IV. The powder blend was free flow-
ing, as demonstrated by the values of the compressibility index (less than 15) and Haus-
ner ratio (less than 1.25). Exhausted shells, after dissolution, were visually observed for
any imperfection or cracks in the coating. There were no visible cracks in the coating
and it was found to be intact in all batches after 8 h of dissolution studies.
To study the effect of pH and to assure a reliable performance, release studies of the
optimized formulation were conducted according to the pH change method (initial 2 h
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Fig. 2. Comparison of promis-
ing formulations with commer-
cial formulations and the theo-
retically desired release profile.
Points represent mean ± SD
(n = 3).
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Fig. 3. Effect of pH, agitation in-
tensity and osmotic pressure of
dissolutiom medium on TRH re-
lease from developed formula-
tions. Points represent mean ± SD
(n = 3).
in pH 1.2, next 2 h in pH 4.5, 2 h in pH 6.8 and finally 2 h in pH 7.4) and compared to re-
lease data in SIF. There was a not a significant difference between different pHs of re-
lease medium on TRH release compared to in vitro data in SIF (Fig. 3). The f1 and f2 val-
ues of batch IVB were found to be 2.65 and 91.85 respectively, taking the release profile
in SIF as reference.
To study the effect of hydrodynamic conditions on TRH release, a release study of
batch IVB was carried out at three different rotational paddle speeds (50, 100, 150 rpm).
There was an insignificant effect of rotational speed on TRH release from developed for-
mulations when all the three release profiles were compared (Fig. 3). The f1 and f2 val-
ues were found to be 4.22 and 85.09 (between 50 and 100 rpm), 3.71 and 85.78 (between
100 and 150 rpm), and 7.77 and 73.33 (between 50 and 150 rpm), respectively.
To study the effect of osmotic pressure, release studies of the optimized formulation
were conducted in media of different osmotic pressure (19.12, 47.32, 94.64 atm). The re-
sults showed that the drug release was highly dependent on the osmotic pressure of the
release media. TRH release from the formulations decreased as the osmotic pressure of
the media increased (Fig. 3). Thus it was concluded that osmotic pumping is the major
mechanism governing drug release from developed formulations.
Before dissolution studies, all membranes (Figs. 4a,b, and c) looked similar and no
porous membrane structure was observed with different levels of plasticizer (PEG-400).
Fig. 4b shows the SEM micrograph of a membrane with no PEG-400 (batch IVA). It shows
a surface morphology similar to that of Fig. 4a, suggesting that there is no evidence of
development of pores in the membrane after the dissolution study. On the other hand,
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Table IV. Properties of the powdered blend, core tablets, and final coated tablets of the optimized
formulation (batch IVB)
Parameter Mean value (± SD)
Bulk density (mg mL–1)a 415
Tap density (mg mL–1)a 464
Compressibility index (%)a 8.69
Hausner ratioa 1.08
Core tablet mass (mg, n = 10)
Coated tablet mass (mg, n = 10)
300.12 (± 5.21)
318.21 (± 4.62)
Core tablet thickness (mm, n = 10)
Coated tablet thickness (mm, n = 10)
4.12 (± 0.02)
4.48 (± 0.02)
Core tablet diameter (mm, n = 10)
Coated tablet diameter (mm, n = 10)
8.11 (± 0.11)
8.32 (± 0.02)
Core tablet hardness (kg cm–2, n = 10)
Coated tablet hardness (kg cm–2, n = 10)
6.12 (± 1.12)
10.24 (± 1.48)
Friability (%, n = 20)b 0.096
Content uniformity (%, n = 20)c 102.46 (± 2.24)
a Property of powdered blend; b property of core tablet; c Property of final coated tablet.
there was formation of pores in membranes of batches IVB and IVC (Figs. 4d,f) after dis-
solution studies. This might be due to the rapid dissolution of the water soluble plasti-
cizer (PEG-400) in dissolution medium. When comparison was made of the membranes
containing different levels of plasticizer (Figs. 4b,d,f), it was found that the membrane
that contained a higher level of plasticizer became more porous after the dissolution studies.
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Fig. 4. SEM micrograph showing the membrane structure of formulation batches IVA, IVB and IVC
(150 mm coat thickness). Panels a, c, and e represent SEM micrographs before the dissolution study
of batches IVA, IVB and IVC, respectively, whereas panels b, d, and f represent SEM micrographs
after the dissolution study of batches IVA, IVB and IVC, respectively.
Kinetics and mechanism of drug release
Dissolution data of the optimized formulation (batch IVB) was fitted to various ma-
thematical models (zero-order, first-order and Higuchi) in order to describe the kinetics
of drug release (17). Smallest value of the sum of squared residuals (SSR), Akaike infor-
mation criterion (AIC) and the best goodness-of-fit test (R2) were taken as criteria for se-
lecting the most appropriate model. Drug release from optimized formulations fitted well
into zero-order kinetics (Table V), confirming that the release from formulations is close
to the desired release profile and drug load dependent.
Reproducibility and accelerated stability study
Reproducibility of the manufacturing procedure was confirmed by preparing three
repeated batches of the final optimized formulation on three different occasions. Release
studies were conducted in SIF and similar release profiles were obtained from all repeated
batches, demonstrating that the manufacturing procedure is reproducible. The f1 and f2
values were found to be 4.11 and 85.07 (between repeat batches 1 and 2), 3.26 and 89.46
(between repeat batches 1 and 3), and 5.23 and 81.68 (between repeat batches 2 and 3),
respectively.
Optimized TRH formulations were packed in strips of 0.04 mm thick aluminum foil
laminated with polyvinyl chloride (PVC). Packed formulations were stored in stability
chambers (Narang Scientific Work, India) maintained at 40 °C and 75 % relative humid-
ity for 6 months (24). Stored formulations of optimized batch with 150-mm coat thicke-
ness were found to be stable in terms of physical properties, hardness, in vitro release
characteristics and dissolution stability (Table VI) even after storage for 6 months. Despite
statistically significant variability in the drug content, the tested formulation adhered to
ICH (24) criterion of  5 % drug content change from its initial value.
In vivo study and in vitro-in vivo correlation
The plasma TRH concentration vs. time profile (Fig. 5) obtained from the in vivo study
clearly shows that the developed formulations (batch IIIB and batch IVB) maintained a
constant therapeutic TRH concentration within the plasma even up to 24 h, as compared
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R Intercept (%) Slope (% h–1) ka SSR AIC
Zero-order 0.9996 –2.9071 9.423 8.371 25.8 15.36
First-order 0.9370 1.9157 0.332 0.3326 216.12 32.36
Higuchi model 0.9903 –36.8103 37.359 37.3597 128.42 26.18
R – correlation coefficient, SSR – sum of squares of residuals, AIC – Akaike information criteria, k – release
rate constant for respective models, a k0 in mg h–1, k1 in h–1 and kH in % h–1/2 for zero-order, first order and
Higuchi rate equations models respectively.
to commercial formulations M1 and M2, which showed a rapid decline in drug concentra-
tion with time. The developed formulations showed lower cmax (but within therapeutic
range) and higher tmax values than commercial tablets (Table VII). Lower cmax for batches
IIIB and IVB indicate avoidance of the risk of exceeding the maximum safe concentra-
tion. Higher tmax for batches IIIB and IVB is indicative of drug release occurring at a slower
rate than from commercial tablets. Significantly higher value of AUC0–24, relative bio-
availability and mean residence time (MRT) for batch IVB compared to M1 and M2 (Ta-
ble VII) further indicate the superiority of the developed formulation over commercial
immediate release (M1) and sustained release (M2) tablets of TRH, in terms of providing
controlled drug release for a longer time and improved bioavailability.
An in vitro-in vivo correlation of batch IVB was carried out using the Wagner-Nelson
method (20). Percent drug dissolved (x) when plotted against percent drug absorbed (y)
gives a good linear regression y = 1.49x + 7.838 (Table VIII). The correlation coefficient R
of 0.9750 indicates a good correlation up to almost 54 % in vitro drug release.
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Fig. 5. Plasma profiles of
TRH following oral adminis-
tration of developed formu-
lations compared to comme-
rcial formulations to healthy
human subjects. Points rep-
resent mean ± SD (n = 6).
Table VI. Batch IVB stabilitya
Parameter Initial 2 month 4 month 6 month
Drug content (% ± SD, n = 20) 102.60 ± 1.44 99.68 ± 1.87b 98.14 ± 1.67b 104.60 ± 1.61b
Hardness (mean ± SD, n = 10) 7.33 ± 1.98 7.98 ± 1.68 7.33 ± 1.48 8.13 ± 1.52
f1 – 2.32 4.52 5.12
f2 – 92.62 84.62 82.24
MDT50 3.004 3.271 3.151 3.208
a 6 months storage at 40 °C and 75 % RH
b Significant difference (p < 0.05) vs. initial value.
CONCLUSIONS
Extended release formulations of TRH were developed based on osmotic technology.
The effect of different formulation variables was studied to optimize the release profile.
Drug release was directly proportional to the level of plasticizer, but inversely related to
the level of swellable polymer and membrane thickness. Release from the developed for-
mulations was independent of pH and agitation intensity of the release media, assuring
the release to be fairly independent of pH and hydrodynamic conditions of the absorp-
tion site. TRH release from the developed formulations was inversely proportional to
the osmotic pressure of the release media, confirming osmotic pumping to be the major
mechanism of drug release. The in vivo study showed that the optimized formulation
(batch IV) achieved a higher value of AUC0–24, relative bioavailability and MRT com-
pared to the commercial formulation of TRH. This study suggests that the developed
optimized formulation (IVB) could perform therapeutically much better than the com-
mercial immediate release (M1) and sustained release (M2) tablets of TRH as potential
prolonged and controlled release dosage forms.
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Table VII. Bioavailability and pharmacokinetic parameters following oral administration of developed
formulations (batches IIIB and IVB) and marketed formulations (M1 and M2) of TRH
Batch cmax (mg mL–1)a tmax (h)
a AUC0–24 (mg h mL–1) a RB1 (%) RB2 (%) MRT (h)
IIIB 0.238 ± 0.024 6.8 ± 0.5 2.457 ± 0.320 123.77 110.87 13.7
IVB 0.220 ± 0.064 7.5 ± 0.4 2.632 ± 0.280 132.59 118.77 14.2
M2 0.270 ± 0.063 4.3 ± 0.4 2.216 ± 0.230 111.63 100 9.1
M1 0.325 ± 0.075 1.7 ± 0.5 1.985 ± 0.310 100.00 89.58 4.2
AUC – area under curve, RB1 – relative bioavailability with reference to M1 (immediate release formulation),
RB2 – relative bioavailability with reference to M2 (sustained release formulation)
a Mean ± SD (n = 6).
Table VIII. Correlation between in vitro percent TRH release and in vivo percent absorption
of TRH from optimized formulation
Time (h) 0 2 4 6 8
In vitro release Fr (%) 0 15.245 34.385 53.665 70.234
In vivo absorption Fa (%) 0 31.431 68.675 96.642 100.801
Fr – drug fraction release
Fa – drug fraction absorbed
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S A @ E T A K
Razvoj i biofarmaceutsko vrednovanje pripravaka za pove}ano osloba|anje
tramadol hidroklorida na principu osmotske tehnologije
PRAMOD KUMAR, SANJAY SINGH i BRAHMESHWAR MISHRA
U radu je opisana priprava i evaluacija pripravaka tramadol hidroklorida (TRH) na
principu osmotske tehnologije. Da bi se postigao `eljeni profil osloba|anja mijenjane su
razli~ite varijable. Pokazalo se da najve}i utjacaj na osloba|anje ljekovite tvari imaju udjeli
polimera koji bubri, plastifikatora i debljina ovojnice polupropusne membrane (SPM).
TRH osloba|anje bilo je proporcionalno udjelu plastifikatora, a obrnuto proporcionalno
udjelu polimera i vrijednosti SPM. Osloba|anje ljekovite tvari bilo je neovisno o pH i
intenzitetu mije{anja, a ovisno o osmotskom tlaku medija. U in vivo studiji provedenoj
na {est zdravih volontera odre|eni su farmakokineti~ki parametri (cmax, tmax, AUC0–24,
MRT) i izra~unata relativna bioraspolo`ivost. Rezultati dobiveni u pokusima in vitro i in
vivo uspore|eni su s dvije vrste komercijalno dostupnih tableta TRH: osloba|anje ljeko-
vite tvari iz pripravka razvijenog u ovom radu bilo je dulje i vi{e kontrolirano. In vitro-in
vivo korelacija (IVIVC) je analizirana prema Wagner-Nelsonovoj metodi. Optimizirani pri-
pravak (IVB) pokazao je dobru IVIV korelaciju (R = 0,9750). Proizvodni proces je bio re-
producibilan i pripravci su bili stabilni tijekom 6 mjeseci u uvjetima ubrzanog starenja.
Klju~ne rije~i: tramadol, pove}ano osloba|anje, osmotski tlak, polimer koji bubri, in vitro-in vivo
korelacija
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